Commentary Open Access
Volume 6 | Issue 3 | DOI: https://doi.org/10.33696/immunology.6.196
Targeting Monocyte Abnormalities in Systemic Lupus Erythematosus through Omics-Based Drug Repurposing
Panagiotis Garantziotis1,2,3.*, Dimitrios Nikolakis4,5,6, Eleni Frangou1,7,8, George Bertsias9,10, Dimitrios T. Boumpas1,11
- 1Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation Academy of Athens, Athens, Greece
- 2Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany
- 3Deutsches Zentrum für Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen
- 4Amsterdam Institute for Gastroenterology Endocrinology and Metabolism, Department of Gastroenterology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
- 5Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology & Immunology Center (ARC), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
- 6Amsterdam Institute for Infection & Immunity, Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
- 7Department of Nephrology, Limassol General Hospital, State Health Services Organization, Limassol, Cyprus
- 8University of Nicosia Medical School, Cyprus
- 9Rheumatology, Clinical Immunology and Allergy Department, Medical School University of Crete, Heraklion, Greece
- 10Laboratory of Auoimmunity-Inflammation, Institute of Molecular Biology and Biotechnology, Heraklion, Greece
- 114th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
Corresponding Author
Panagiotis Garantziotis, garantziotis.p@gmail.com
Received Date: April 10, 2024
Accepted Date: May 22, 2024
Garantziotis P, Nikolakis D, Frangou E, Bertsias G, Boumpas DT. Targeting Monocyte Abnormalities in Systemic Lupus Erythematosus through Omics-Based Drug Repurposing. J Cell Immunol. 2024;6(3):113-116.
Copyright: © 2024 Garantziotis P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
The Pathogenesis of Continuous Spike and Waves during Slow Sleep Syndrome: Short Communication
Continuous spikes during slow wave sleep (CSWS) syndrome is an age-related and self-limited severe epileptic encephalopathy characterized by electrical status epilepticus in sleep (ESES) on electroencephalogram, seizures, and developmental regression
Sleep Disturbances are a Significant Predictor of Chikungunya Arthritis Flare Severity
Chikungunya virus (CHIKV) is an alphavirus transmitted by mosquitoes that causes debilitating arthritis. In a cohort of 500 Colombian patients, one quarter reported joint pain 20 months after infection, and further, 1 out of 8 had joint pain three years after infection.
Impact of Sleep on Autophagy and Neurodegenerative Disease: Sleeping Your Mind Clear
Sleep is an evolutionarily conserved phenomenon which has survived tremendous evolutionary pressures. Its disruption has deleterious implications for human health. The importance of sleep is illustrated by the fact that sleep deprivation in many animals leads to death. While sleep is tightly regulated by a combination of intrinsic and extrinsic factors it becomes progressively disrupted in old age and in neurodegenerative diseases including Alzheimer’s disease (AD), frontotemporal dementia (FTD), Parkinson’s disease (PD) and Huntington’s disease (HD).
The Issue of Monocyte Activation in ASD: Troubles with Translation
Autism spectrum disorder (ASD) prevalence has increased year on year for the past two decades and currently affects 1 in 44 individuals in the US. An increasing number of studies have pointed to increased immune activation as both an etiological agent and also involved in the ongoing pathological process of ASD. Both adaptive and innate immune responses have been implicated. Evidence of innate dysregulation has so far included increased production of innate inflammatory cytokines, increased cell numbers, and altered activation in monocytes in the blood and microglia in the brain.
Treatment of Sleep Disorders in Children with Atopic Dermatitis: What's New?
Atopic dermatitis (AD), also known as atopic eczema, is a chronic and inflammatory disease caused by an interaction of genetic, immunological, and environmental factors. It is characterized by skin lesions and itching and progresses with periods of improvement and worsening.